60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP) Stock Price

SXTPStock

$1.13−78.57%52W

Market Cap$3.97M

P/E—

PEG Ratio—

Div yield—

Beta2.52

SXTP Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-76.29%

Price vs S&P 500 (4W)-31.05%

VGM Score33.03

Book Value / Share (Quarterly)$1.83

P/TBV (Annual)0.66x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)40.21%

Cash Flow / Share (Quarterly)$-3.13

Price vs S&P 500 (YTD)-58.76%

Gross Margin (TTM)39.60%

Net Profit Margin (TTM)-576.30%

EPS (TTM)$-9.79

10-Day Avg Trading Volume0.07M

EPS Excl Extra (TTM)$-9.79

Revenue Growth (5Y)-8.37%

EPS (Annual)$-10.99

ROI (Annual)-203.69%

Gross Margin (Annual)44.52%

Net Profit Margin (5Y Avg)-890.06%

Cash / Share (Quarterly)$1.27

Revenue Growth QoQ (YoY)-36.75%

ROA (Last FY)-137.25%

Revenue Growth TTM (YoY)66.12%

EBITD / Share (TTM)$-7.74

Operating Margin (TTM)-604.05%

Cash Flow / Share (Annual)$-6.08

P/B Ratio0.65x

P/B Ratio (Quarterly)0.96x

Net Income / Employee (Annual)$-2,455,100

EV / Revenue (TTM)-0.04x

Net Interest Coverage (TTM)-0.40x

ROA (TTM)-131.78%

EPS Incl Extra (Annual)$-10.99

Current Ratio (Annual)2.66x

Quick Ratio (Quarterly)1.96x

3-Month Avg Trading Volume0.10M

52-Week Price Return-78.57%

Revenue / Employee (TTM)$438,300

Tangible BV / Share (Quarterly)$1.74

P/S Ratio (Annual)2.23x

Asset Turnover (Annual)0.26x

52-Week High$8.62

Operating Margin (5Y Avg)-966.28%

EPS Excl Extra (Annual)$-10.99

CapEx CAGR (5Y)25.17%

26-Week Price Return-65.05%

Quick Ratio (Annual)1.77x

13-Week Price Return-27.52%

Total Debt / Equity (Annual)0.04x

Current Ratio (Quarterly)3.34x

Enterprise Value$-47,800

Revenue / Share Growth (5Y)39.94%

Asset Turnover (TTM)0.23x

Revenue / Employee (Annual)$469,700

Inventory Turnover (Annual)1.42x

Pretax Margin (Annual)-522.91%

Cash / Share (Annual)$2.37

3-Month Return Std Dev71.74%

Gross Margin (5Y Avg)20.59%

Net Income / Employee (TTM)$-2,525,900

ROE (Last FY)-212.67%

Net Interest Coverage (Annual)-35.03x

EPS Basic Excl Extra (Annual)$-10.99

Receivables Turnover (TTM)3.19x

Total Debt / Equity (Quarterly)0.03x

EPS Incl Extra (TTM)$-9.79

Receivables Turnover (Annual)2.83x

ROI (TTM)-192.29%

P/S Ratio (TTM)2.39x

Pretax Margin (5Y Avg)-893.97%

Revenue / Share (Annual)$2.10

Tangible BV / Share (Annual)$2.78

Price vs S&P 500 (52W)-96.88%

Year-to-Date Return-46.80%

5-Day Price Return-3.57%

EPS Normalized (Annual)$-10.99

ROA (5Y Avg)-221.05%

Net Profit Margin (Annual)-522.69%

Month-to-Date Return-7.69%

EBITD / Share (Annual)$-11.51

Operating Margin (Annual)-550.60%

LT Debt / Equity (Annual)0.04x

LT Debt / Equity (Quarterly)0.03x

EPS Basic Excl Extra (TTM)$-9.79

P/TBV (Quarterly)1.01x

P/B Ratio (Annual)0.62x

Inventory Turnover (TTM)0.94x

Pretax Margin (TTM)-576.56%

Book Value / Share (Annual)$2.98

Price vs S&P 500 (13W)-30.31%

Beta2.52x

Revenue / Share (TTM)$0.76

ROE (TTM)-200.06%

52-Week Low$1.02

gGradeD

mGradeD

vgmGradeD

SXTP Earnings Surprise History

Q2 25-4.33est. -4.96

Q3 25-2.53est. -1.84

Q4 25-8.17est. -2.00

Q1 26-1.21est. -0.99

Q2 26-0.86est. -0.89

SXTP Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.13

4.00

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
SXTP60 Degrees Pharmaceuticals, Inc. Common Stock	—	D	D	$1.13
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About 60 Degrees Pharmaceuticals, Inc. Common Stock

60 Degrees Pharmaceuticals develops specialty pharmaceutical therapies for infectious diseases, including COVID-19, fungal, tick-borne, and viral infections. The company uses biological science and applied research to advance its pipeline toward commercialization.